TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Rohto Pharmaceutical Co ( (JP:4527) ) just unveiled an announcement.
Rohto Pharmaceutical Co. reported a significant increase in its financial performance for the six months ended September 30, 2025, with net sales rising by 18.1% and profit attributable to owners of the parent increasing by 36.6% compared to the previous year. The company also announced a revision in its dividend forecast and highlighted the inclusion of Rohto MediLuxe Europe S.A.S.U. in its consolidation scope, indicating strategic expansion and a positive outlook for stakeholders.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2684.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry. It is known for its production of health and wellness products, focusing on both domestic and international markets.
Average Trading Volume: 641,393
Technical Sentiment Signal: Sell
Current Market Cap: Yen560.7B
Find detailed analytics on 4527 stock on TipRanks’ Stock Analysis page.